We’re helping to change how we think about #EarlyCancerDetection for #LungCancer. With the help of #Multiomics data, our team is dedicated to providing patients with a noninvasive detection option for early-stage lung cancer. Check out more from our latest study on our findings below.
PrognomiQ Inc
Biotechnology Research
San Mateo, California 6,776 followers
Transform healthcare and early disease detection through the power of multi-omics data.
About us
PrognomiQ aims to generate proteomic information with high accuracy, scale and speed. This proteomic data will be complemented with genomic, metabolomic and other health information to deliver first-in-class test products that enable early disease detection and treatment. Powerful, Untapped Disease Insights Built on a Proteomics Foundation: Until now, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes. These barriers have now been largely addressed through next generation tools that can elucidate complex proteomics at scale. Complementary Molecular Information: Genomic data has made clear contributions to researchers’ abilities to understand and more precisely treat disease, but it is has shown limited impact on early-stage disease detection. Proteomics provides direct information on the biological state of a cell, including disease at its earliest state, but proteomics data has been technically difficult to generate – until now. By complementing the new sources of proteomics data with genomics and other data, such as metabolomics, we now have the tools to generate powerful multi-omics data that will be the key to unlock the detection and treatment of disease at its earliest stages, when these diseases are most likely to be cured. Unlocking Disease Detection and Treatment with Multi-omics Data: We designed our proprietary multi-omics platform around the most robust approaches to generating proteomic, genomic and metabolomics data at scale, including the use of the Proteograph technology platform from the life science tools company Seer (NASDAQ: SEER) whom PrognomiQ spun out of in 2020.
- Website
-
https://prognomiq.com
External link for PrognomiQ Inc
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Mateo, California
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
1900 Alameda de Las Pulgas
Suite 100
San Mateo, California 94403, US
Employees at PrognomiQ Inc
Updates
-
Our team is dedicated to revolutionizing the detection and early treatment of cancer and other complex diseases. Learn more about our mission: https://prognomiq.com/
-
-
Last week was eventful at the American Society For Mass Spectrometry (ASMS) 2024 annual meeting! Our #PrognomiQ team enjoyed connecting with everyone during our presentations. #ASMS2024
-
-
Attending #ASMS2024? This morning don’t miss Bruce Wilcox, Ph.D, our Chief Technology Officer discuss more about our multicancer study with our deep unbiased plasma proteomics platform. See you there!
-
-
Our #PrognomiQ team is looking forward to this year’s American Society For Mass Spectrometry (ASMS) annual meeting in Anaheim, CA. Next week we will share 4️⃣ poster presentations and 2️⃣ talks. #ASMS2024 +++ Sunday, June 2: - 8:00am – 9:45am: PrognomiQ’s journey translating large-scale discovery to a clinical proteomics test. [Thermo Plenary Talk] Tuesday, June 4: -10:30am - 2:30pm: High-throughput Quantification of 802 Peptides in Blood Plasma using 6495D Triple Quadrupole and Evosep One. [Poster TP 043] Thursday, June 6: -8:30am: Deep unbiased plasma proteomics biomarker study in a ~3,000 subject multicancer cohort. [Talk ThOA] -10:30am - 2:30pm: Translation of Proteograph XT Nanoparticle-Enriched Plasma proteomic features to a targeted assay. [Poster ThP 788] -10:30am - 2:30pm: Novel Hybrid Nominal Mass Instrument Enables Rapid Development of Large-Scale Targeted Plasma Proteomics Assays. [Poster ThP 799] -10:30am - 2:30pm: Deep plasma proteomics enables identification of sample-swap issues in a large multi-omics discovery study. [Poster ThP 498]
-
-
#ICYMI last week GenomeWeb shared an article on the future of #Multiomics, featuring PrognomiQ and how we are overcoming challenges in working with multi-omics data. Check it out below!
The ability to perform larger and more complex multiomic experiments raises questions and opportunities around integrating data and extracting scientific insights.
As Multiomics Progresses, Data Challenges Come to the Fore
genomeweb.com
-
“The combination of proteomic data with genomic, metabolomic, epigenomic, and transcriptomic data provides unparalleled levels of novel biological insights which could lead to transformative new approaches to diagnostic and therapy development.” -Philip Ma, PrognomiQ, CEO and Founder Read more about our mission in our CEO and Founder’s exclusive interview with Newsweek Investment Reports.
Philip Ma, CEO & Founder, PrognomiQ
investmentreports.co
-
PrognomiQ is dedicated to working with the FDA to bring our innovative diagnostic products to patients. Read more on The Wall Street Journal below!
Lab-Testing Startups Brace for FDA Rule Change
wsj.com
-
Our team is dedicated to revolutionizing the detection and early treatment of cancer and other complex diseases. Learn more about our mission at https://prognomiq.com/.
PrognomiQ Is Enabling Early Disease Detection And Treatment
https://prognomiq.com
-
PrognomiQ CEO and Founder Philip Ma, recently spoke with GenomeWeb about our latest positive data in early #LungCancer detection using #Multiomics data. Learn more about our technology and recent data in the article below.
PrognomiQ Aims to Launch Multiomic Lung Cancer Screening Test Buoyed by Positive Early Data
genomeweb.com